[1] |
Rueda LJ, Motta A, Pabón JG, et al. Epidemiology of rosacea in Colombia[J]. Int J Dermatol, 2017,56(5):510⁃513. doi: 10. 1111/ijd.13491.
|
[2] |
Johnston SA, Krasuska M, Millings A, et al. Experiences of rosacea and its treatment: an interpretative phenomenological analysis[J]. Br J Dermatol, 2018,178(1):154⁃160. doi: 10.1111/bjd.15780.
|
[3] |
Tan J, Steinhoff M, Berg M, et al. Shortcomings in rosacea diagnosis and classification[J]. Br J Dermatol, 2017,176(1):197⁃199. doi: 10.1111/bjd.14819.
|
[4] |
Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel[J]. Br J Dermatol, 2017,176(2):431⁃438. doi: 10.1111/bjd.15122.
|
[5] |
Forero Molina MA, Garcia E, Gonzalez⁃Devia D, et al. A 17⁃year⁃old male with a small bowel neuroendocrine tumor: flushing differential diagnosis[J]. World Allergy Organ J, 2017,10(1):30. doi: 10.1186/s40413⁃017⁃0161⁃4.
|
[6] |
Sadeghian A, Rouhana H, Oswald⁃Stumpf B, et al. Etiologies and management of cutaneous flushing: nonmalignant causes[J]. J Am Acad Dermatol, 2017,77(3):391⁃402. doi: 10.1016/j.jaad.2016.12.031.
|
[7] |
Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis[J]. J Clin Oncol, 2009,27(17):2831⁃2837. doi: 10. 1200/JCO.2008.19.6253.
|
[8] |
Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update[J]. J Am Acad Dermatol, 2018,78(4):786⁃792.e8. doi: 10.1016/j.jaad.2017.09.016.
|
[9] |
Egeberg A, Ashina M, Gaist D, et al. Prevalence and risk of migraine in patients with rosacea: a population⁃based cohort study[J]. J Am Acad Dermatol, 2017,76(3):454⁃458. doi: 10. 1016/j.jaad.2016.08.055.
|
[10] |
Egeberg A, Hansen PR, Gislason GH, et al. Patients with rosacea have increased risk of depression and anxiety disorders: a danish nationwide cohort study[J]. Dermatology, 2016,232(2):208⁃213. doi: 10.1159/000444082.
|
[11] |
Scharschmidt TC, Yost JM, Truong SV, et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment[J]. Arch Dermatol, 2011,147(1):123⁃126. doi: 10.1001/archdermatol.2010.413.
|
[12] |
Schaller M, Almeida LM, Bewley A, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel[J]. Br J Dermatol, 2017,176(2):465⁃471. doi: 10.1111/bjd.15173.
|
[13] |
Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea[J]. J Eur Acad Dermatol Venereol, 2017,31(11):1775⁃1791. doi: 10.1111/jdv.14349.
|
[14] |
Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase Ⅲ clinical trials evaluating anti⁃inflammatory dose doxycycline (40⁃mg doxycycline, USP capsules) administered once daily for treatment of rosacea[J]. J Am Acad Dermatol, 2007,56(5):791⁃802. doi: 10.1016/j.jaad.2006.11.021.
|
[15] |
Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea[J]. J Dermatol, 2015,42(1):64⁃69. doi: 10.1111/1346⁃8138.12687.
|
[16] |
van der Linden M, van Ratingen AR, van Rappard DC, et al. DOMINO, doxycycline 40 mg vs. minocycline 100 mg in the treatment of rosacea: a randomized, single⁃blinded, noninferiority trial, comparing efficacy and safety[J]. Br J Dermatol, 2017,176(6):1465⁃1474. doi: 10.1111/bjd.15155.
|
[17] |
Two AM. Minocycline as an alternative to doxycycline in the treatment of rosacea[J]. Br J Dermatol, 2017,176(6):1426. doi: 10.1111/bjd.15514.
|
[18] |
Uslu M, Şavk E, Karaman G, et al. Rosacea treatment with intermediate⁃dose isotretinoin: follow⁃up with erythema and sebum measurements[J]. Acta Derm Venereol, 2012,92(1):73⁃77. doi: 10.2340/00015555⁃1204.
|
[19] |
van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments[J]. Br J Dermatol, 2019,181(1):65⁃79. doi: 10.1111/bjd.17590.
|
[20] |
Asai Y, Tan J, Baibergenova A, et al. Canadian clinical practice guidelines for rosacea[J]. J Cutan Med Surg, 2016,20(5):432⁃445. doi: 10.1177/1203475416650427.
|
[21] |
Two AM, Wu W, Gallo RL, et al. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors[J]. J Am Acad Dermatol, 2015,72(5):749⁃760. doi: 10.1016/j.jaad. 2014.08.028.
|
[22] |
Aubdool AA, Brain SD. Neurovascular aspects of skin neurogenic inflammation[J]. J Investig Dermatol Symp Proc, 2011,15(1):33⁃39. doi: 10.1038/jidsymp.2011.8.
|
[23] |
Gilman SE, Trinh NH, Smoller JW, et al. Psychosocial stressors and the prognosis of major depression: a test of Axis IV[J]. Psychol Med, 2013,43(2):303⁃316. doi: 10.1017/S0033291712 001080.
|
[24] |
Weber MD, Godbout JP, Sheridan JF. Repeated social defeat, neuroinflammation, and behavior: monocytes carry the signal[J]. Neuropsychopharmacology, 2017,42(1):46⁃61. doi: 10.1038/ npp.2016.102.
|
[25] |
Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases(review)[J]. Mol Med Rep, 2016,13(4):3391⁃3396. doi: 10.3892/mmr.2016.4948.
|
[26] |
Vidal Yucha SE, Tamamoto KA, Kaplan DL. The importance of the neuro⁃immuno⁃cutaneous system on human skin equivalent design[J]. Cell Prolif, 2019,52(6):e12677. doi: 10.1111/cpr. 12677.
|
[27] |
Hinwood M, Tynan RJ, Charnley JL, et al. Chronic stress induced remodeling of the prefrontal cortex: structural re⁃organization of microglia and the inhibitory effect of minocycline[J]. Cereb Cortex, 2013,23(8):1784⁃1797. doi: 10.1093/cercor/bhs151.
|
[28] |
Pietschke K, Schaller M. Long⁃term management of distinct facial flushing and persistent erythema of rosacea by treatment with carvedilol[J]. J Dermatolog Treat, 2018,29(3):310⁃313. doi: 10.1080/09546634.2017.1360991.
|
[29] |
Hsu CC, Lee JY. Pronounced facial flushing and persistent erythema of rosacea effectively treated by carvedilol, a nonselective β⁃adrenergic blocker[J]. J Am Acad Dermatol, 2012,67(3):491⁃493. doi: 10.1016/j.jaad.2012.04.017.
|
[30] |
Weihe E, Schütz B, Hartschuh W, et al. Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system[J]. J Comp Neurol, 2005,492(3):370⁃379. doi: 10.1002/cne.20745.
|